TO THE EDITOR: I read the recent article by Daar and colleagues (1) with great interest. A portion of the results of this important study has already been published (2), with the more recent results still raising comments and questions.
TO THE EDITOR:
On behalf of the AIDS Clinical Trials Group (ACTG) Study A5202 Team, Daar and colleagues (1) reported the results of an open-label, randomized equivalence trial to compare atazanavir plus ritonavir or efavirenz with placebo-controlled abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine. We believe that the A5202 study has some biases that may substantially compromise its internal validity.
The open-label design of the study has probably influenced adjudication of the primary outcomes, such as time to the occurrence of adverse effects or tolerability, thus making the study prone to performance bias. It was able to declare equivalence among the compared treatments on the basis of previously defined boundaries only in a post hoc assessment. The authors state that this differed from the A5142 study (2) by randomizing and blinding the nucleoside reverse transcriptase inhibitors (NRTI) and by using atazanavir plus ritonavir. The A5202 study blinded only patients assigned to the NRTI, and unblinding occurred in patients with high viral load status at screening at the recommendation of the data safety monitoring board. The prespecified analysis of the A5202 study demonstrated that a ritonavir-boosted protease inhibitor was not able to reach the noninferiority margin (compared with efavirenz) in a way similar to that of the A5142 study (2) . Furthermore, the study did not find substantial differences on clinical outcomes, which are evidently less prone to detection bias.
Loss to follow-up in the A5202 study was high, especially in the efavirenz-based groups, as stated in the note that accompanied the early-release version published on the Annals of Internal Medicine Web site and acknowledged by the authors (1) . One third of the patients in the study changed or discontinued the originally allocated regimen. For example, in the efavirenz-abacavir-lamivudine group, only 59% of patients completed follow-up with the assigned regimen, thus resulting in a substantial attrition bias.
For an adequate analysis of noninferiority or equivalence trials, it is imperative to report both on-treatment and intention-to-treat analysis (3, 4) . The study did not provide a per-protocol analysis, making it difficult to conclusively state that noninferiority or equivalence was present among the studied interventions. In the context of the aforementioned limitations, the study has limitations in its internal validity; therefore, its results do not provide enough evidence to support the conclusions that atazanavir plus ritonavir and efavirenz provide similar antiviral activity when used with abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine.
IN RESPONSE: Dr. Flandre raises important points regarding the ACTG Study A5202 results; however, the abstract's conclusion does not stand alone. The Results section of the abstract and the Results and Discussion sections of the manuscript state that the equivalence boundary was not met. We do believe that the similarity in response rates is relevant to clinicians considering these treatment options. Differences in baseline HIV-1 RNA values have been addressed in a secondary analysis adjusting for this as continuous and categorical variables (Ͻ50 000 copies/mL, 50 000 to Ͻ100 000 copies/mL, 100 000 to Ͻ500 000 copies/mL, or Ն500 000 copies/mL), with the treatment effect estimate showing similar results to the primary analysis. The HRs and 95% CIs when baseline HIV-1 RNA was analyzed as continuous and categorical variables were 1.11 (0.81 to 1.54) and 1.06 (0.77 to 1.47) for abacavir-lamivudine and 1.01 (0.70 to 1.46) and 1.04 (0.72 to 1.51) for tenofovir disoproxil fumarate-emtricitabine, respectively.
Prespecified equivalence boundaries were based on the relative treatment difference of the HR (specified as 0.71 to 1.40). The paper's Statistical Analysis section states that an HR of 1.40 with a 32% event rate would represent a 96-week difference in probability of VF of approximately 10%. The VF rate makes the current equivalence definition very strict. With the observed rate of approximately 15%, an HR of 1.40 would correspond to an approximately 5% absolute difference, and a 10% difference would correspond to HR boundaries of 0.56 to 1.77.
Dr. Kuchenbecker and colleagues are correct that the drugs compared in this study were open-label; however, blinding protease and nonnucleoside reverse transcriptase inhibitors is challenging and rarely done in recent HIV treatment trials-we acknowledged this in the manuscript as a limitation of the study. We stand by our statement that A5202 was different in design and results from A5142 (1) . Unlike the A5142 study, the A5202 study randomly assigned patients to commonly used NRTIs in a blinded fashion and also used atazanavir-ritonavir, which is a preferred agent; this is no longer true for the lopinavir-ritonavir used in A5142 (2) . Although the A5202 study was unable to declare equivalence, response rates by all other measures were similar between the 2 regimens. Compared with efavirenz in the A5142 study, the time to VF was significantly shorter with lopinavir-ritonavir (HR, 0.63 [CI 0.45 to 0.87]; P ϭ 0.0006).
We agree with the commentators and acknowledged the relatively high loss to follow-up in the manuscript. We did several sensitivity analyses to address potential attrition bias (Appendix Table 2 in the article), including as-treated analyses in which time to VF failure was censored at modification of the third drug that showed results similar to those of the primary intention-to-treat analysis. 
Eric S. Daar, MD

A Transmission Model of the 2010 Cholera Epidemic in Haiti
TO THE EDITOR: The article by Tuite and colleagues (1) proposed a spatially explicit scheme reproducing the sequence and the timing of regional cholera epidemics through waterborne and person-to-person transmission of cholera. Two additional modeling studies of the ongoing Haiti cholera outbreak and its controls were independently and almost simultaneously published (2, 3). In particular, a similar transmission model, based on a finer spatial detail of the affected communities and on alternative descriptions of hydrologic and human mobility drivers of pathogen dispersal (4, 5) , has been likewise applied to the unfolding Haiti epidemic (3). Despite differences in the assumptions, the results regarding the effect of control strategies, such as vaccination and sanitation, are similar. However, the article by Bertuzzo and colleagues (3) pointed out that larger intervention efforts involve nontrivial effects, with sanitation exhibiting a threshold-like behavior in effectiveness.
From a modeling standpoint, the main difference between the approaches is that Tuite and colleagues (1) neglect the role of asymptomatic patients who do not report to a hospital, which is suggested to be a critical factor in cholera epidemics, particularly those in Haiti (2, 3) . Asymptomatic patients acquire immunity, thus reducing the number of persons in a region who are susceptible to the disease. Figure 4 in Tuite and colleagues' article shows that their model with realistic values of the basic reproductive number (R 0 ϭ 2.78 or 2.90) fits the initial phases of the epidemic but would predict an excessive number of reported cases at later stages. To overcome this, they propose that the effective reproductive number decreases from 3 to 0.5 in the first 3 months of the epidemic, owing to disease-control interventions that would have effectively prevented thousands of cases. A 6-fold decrease of the reproductive number-if asymptomatic patients are not accounted for and the compartment of susceptibles is not depleted-implies a 6-fold decrease of transmission rates.
These figures seem unrealistic, especially compared with the sanitation intervention that Tuite and colleagues analyzed (1): Providing vaccines or clean water to 500 000 persons clearly represents a major effort largely exceeding the disease-control interventions adopted in the first 3 months of cholera insurgence in Haiti, yet it would lead to a much smaller decrease in the transmission rate. This apparent paradox is solved by adopting a model in which asymptomatic infections are accounted for (2, 3). This does not require reproductive numbers to decrease with time because of unspecified disease-control measures to prevent an excess of persons who were calculated to be infected, which is an artifact of neglecting asymptomatic patients (2, 3).
Despite differences in methods, a comparative study on the limits and validity of modeling large-scale epidemic management suggests that such tools should be seen as essential components of future control of cholera epidemics. 
IN RESPONSE:
We welcome the opportunity to clarify our analysis for Dr. Rinaldo and colleagues. We modeled a pool of infective patients that included both hospitalized and nonhospitalized individuals, but calibrated the model to reproduce hospitalized cases that were accurately measured. Our analysis of vaccines and water was not intended to represent the massive and far more robust multiagency public health response to the Haitian cholera epidemic; rather, it was intended to explore the projected relative effects of low levels of vaccination and water distribution. We did not distinguish symptomatic and asymptomatic cases in our model.
Dr. Rinaldo and colleagues suggest that the marked decline in the rate of growth of Haiti's cholera epidemic resulted from asymptomatic infection of large numbers of individuals in the population, and that the epidemic effectively stopped by itself. They suggest that our empirical reduction in effective reproductive number (which they misstate as reduction in R 0 ) is problematic and fails to capture the degree to which population immunity resulted in transient control of the epidemic. Recent events in Haiti show this thesis to be implausible, and our modeling approach has unfortunately been somewhat validated by the recent large surge in cholera cases in Haiti since early May 2011. This surge has been particularly marked in the capital region and in the south of the country, as our model projected (1) .
It is important to distinguish the basic reproductive number of a disease (R 0 ), which is the average number of secondary cases of infection created by a primary case introduced into a totally susceptible population in the absence of intervention (2), from the effective reproductive number, which is the reproductive number in the presence of immunity or intervention (often denoted R e ). Dr. Rinaldo and colleagues confuse these concepts. For R e to decline from around 3 to around 0.5 solely on the basis of immunity, approximately 85% of the Haitian population would have had to be infected in a 3-month period (2). This would require implausibly short "serial intervals" between cases for a disease with an R 0 of 3 (3) and would also have resulted in sufficient herd immunity to make the recent epidemic surge in cholera cases impossible (2) . Better data are needed for the modeling and control of cholera in Haiti, but to be credible, modelers need to consider the important and hard-to-measure effects of public health responders in the successful control of epidemics. 
Effect of the Centers for Medicare & Medicaid Services Policy About Deep Sedation on Use of Propofol
TO THE EDITOR:
Rex's article (1) on Medicare policy as it affects use of propofol for procedural sedation confuses the standards set by the Centers for Medicare & Medicaid Services (CMS) for deep sedation. The author, like any physician-anesthesiologist or not-is permitted under Medicare policy to administer deep sedation or general anesthesia if his or her facility has been granted privileges for doing so. The CMS does not forbid gastroenterologists from administering sedatives and anesthesia, but it does forbid them from delegating this responsibility to an endoscopy nurse while occupied with the endoscopy procedure-a policy shared by dozens of state nursing boards. The U.S. Food and Drug Administration's "black box" warning for propofol forbids its use while performing a procedure, such as endoscopy. This reflects the judgment that the administration of such potent drugs requires the undivided attention of the responsible physician. The Institute for Safe Medication Practices, the American Society of Anesthesiologists (ASA), and other groups take the same view on the hazard of multitasking with deep sedation or anesthesia.
These groups all go further than CMS in stating that because of the unique characteristics of propofol, its use also requires that the user be trained in the administration of anesthesia. The CMS relies on individual institutions under a single anesthesia service to define the qualifications of those given privileges to administer sedation and anesthesia. Rex needs to look no further than oral surgery for an example of a group that has established explicit and uniform training requirements for using anesthesia in a nonanesthesiologist-based practice. The failure of gastroenterology as a specialty to establish such requirements is the real barrier to the acceptance of the practice he proposes. 
IN RESPONSE:
Endoscopists have traditionally administered opioids and benzodiazepines for sedation-either themselves or by assigning the task to a registered nurse under their supervision-with an excellent published safety record (1). Many state nursing boards allow the use of this model, including for administration of propofol. There is extensive evidence that this model has been used with even better safety for administration of propofol titrated to moderate as well as deep sedation (1). Dr. Hannenberg cites no evidence to the contrary; rather, he cites the 20-year-old package insert for propofol and the opinions of The Institute for Safe Medication Practices and the ASA. Although Dr Hannenberg cites no conflicts of interest, many members of the ASA have conflicts of interest with regard to this opinion. Assessment of evidence by parties without conflicts would ideally decide the issue. The impractical suggestion by Dr Hannenberg that endoscopists utilize another nonanesthesiologist physician who is not involved in the procedure to administer propofol would result in the same problem of cost-ineffective care created by the use of anesthesia specialists to sedate low-risk patients for routine procedures.
Several training documents have also been created by gastroenterologists to guide the training of endoscopists who wish to learn how to administer and direct the administration of propofol (1). The ASA also published an evidence-based guideline on administration of sedation by nonanesthesiologists, which included recommendations for administration of deep sedation (2) . None of the subsequent statements by the ASA regarding this issue have quoted evidence.
Douglas K. Rex, MD Indiana University Hospital Indianapolis, IN 46202
Physical examination showed a hanging right corner of her mouth, a positive Chvostek sign, and elevated blood pressure (140/100 mm Hg). We ruled out a focal neurologic lesion with cerebral computed tomography. Blood tests revealed reduced ionized calcium and magnesium levels (1.89 mmol/L [7.56 mg/dL] and 0.38 mmol/L [0.76 mEq/L], respectively) and levels of parathyroid hormone and cholecalciferol that were within normal ranges (Figure) .
The patient was administered intravenous calcium gluconate, which was followed by improvement in her tetany symptoms, but blood pressure remained elevated (155/105 mm Hg). Because gastroscopy revealed Helicobacter pylori-positive gastritis, we doubled the dose of pantoprazole and started antibiotic eradication therapy. Low levels of ionized calcium and magnesium persisted in blood and urine samples despite continued intravenous administration of these minerals, and blood pressure increased to a maximum of 160/100 mm Hg. When we became aware of reports describing an association between PPIs and hypomagnesemia, we stopped therapy with pantoprazole and replaced it with ranitidine, 150 mg twice daily. The patient's tetany symptoms and signs resolved within 48 hours. In addition, blood pressure had returned to normal 6 days later, and her ionized serum calcium and magnesium levels had returned to those observed before the patient started pantoprazole therapy. During this period, her serum magnesium level was inversely related to her systolic and diastolic blood pressure (Pearson correlation coefficients, Ϫ0.82 and Ϫ0.83, respectively; P Ͻ 0.05).
After the patient gave consent, we readministered pantoprazole, 40 mg/d, with calcium and magnesium supplementation. She had an elevated blood pressure (140/90 mm Hg) and decreased serum magnesium concentration (0.53 mmol/L [1.06 mEq/L]) 4 days later. We advised her not to take PPIs in the future. During 2 years of follow-up, the patient has had new exacerbations of Crohn disease, some requiring surgery, but no tetany, arterial hypertension, or major electrolyte abnormalities.
Discussion: The patient had no history of arterial hypertension, and we ruled out renal or endocrine causes of arterial hypertension. Other investigators have reported that magnesium affects vascular tone by several mechanisms, one of which is competing with calcium and modulating the level of intracellular total and free calcium (4, 5) . We suggest that magnesium and calcium be measured during PPI administration, particularly in patients with malabsorption or prehypertension. mouse antibodies in our patient's serum. Heterophilic blocking reagent 1 contains mouse immunoglobulins that prevent human antimouse antibodies from binding to mouse antibodies, and probably explains why addition of this reagent to the patient's serum reduced BNP levels with our usual assay. As the antibodies in BNP assays are often derived from mice, a human antimouse antibody more commonly interferes with BNP assays than human antibodies directed against other animals (4, 5). 
Xiao-Hong
